Is Tirzepatide the New Game Changer in Type 2 Diabetes?
<b>Background:</b> Tirzepatide (TZP) is a once-weekly glucagon-like peptide 1 (GLP-1) and glucose-dependent-insulinotropic-polypeptide (GIP) receptor co-agonist approved for T2D. TZP provides promising evidence in improving glucose control and weight loss in T2D and obesity across precli...
Main Authors: | , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2024-02-01
|
Series: | Endocrines |
Subjects: | |
Online Access: | https://www.mdpi.com/2673-396X/5/1/5 |